doi: 10.4103/jfmpc.jfmpc_480_19
The randomised, double-blind, placebo-controlled study enrolled 2,339 adults with obesity or overweight and at least one weight-related health condition (such as high blood pressure or heart disease) but without diabetes
What outcomes do you claim, and what is the evidence
Kim points to a randomized trial in patients with alcohol use disorder: The number of drinking days didnt change, but people drank less on the days they did drink
The FDA approved once-daily oral semaglutide (Wegovy) at 25 mg on 22 December 2025, making it the first oral GLP-1 approved specifically for chronic weight management in the US
GLP-1 is a natural hormone that helps control appetite and boost weight loss, while Ozempic is an effective medication that mimics GLP-1s effects for lasting results